Califf Clears First Senate Hurdle, But Could FDA’s Abortion Pill Access Decision Be A Headache?
Executive Summary
Robert Califf’s nomination to be the next US FDA commissioner squeaked out of the Senate health committee, but a significant number of Republicans are against his confirmation over the agency’s recent decisions on abortion drugs.
You may also be interested in...
Industry Looks To Califf’s Leadership As It Negotiates User Fee Deal, Fights Pandemic
After the US Senate barely greenlit Robert Califf to again helm the US FDA, industry sources say they look forward to him taking an active role in ensuring the next user fee deal is successful.
Abortion Pill Mifepristone Will No Longer Require In-Person Pick Up, US FDA Concludes
REMS modification implemented for the duration of the pandemic will become permanent, the agency determines in response to lawsuit. FDA adds a requirement that pharmacies dispensing the drug be certified.
Opioids, Abortion, And Drug Advertising: How A Califf-Led FDA Might Address Hot Button Rx Topics
Robert Califf offers some interesting clues as to how he’d handle top drug policy issues in his Senate confirmation hearing.